Outpatient treatment with 131I-anti-B1 antibody

Radiation exposure to family members

F. J. Rutar, Samuel C. Augustine, D. Colcher, J. A. Siegel, D. A. Jacobson, M. A. Tempero, V. J. Dukat, M. A. Hohenstein, L. S. Gobar, J. M. Vose

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The Nuclear Regulatory Commission (NRC) regulations that govern release of patients administered radioactive material have been revised to include dose-based criteria in addition to the conventional activity-based criteria. A licensee may now release a patient if the total effective dose equivalent to another individual from exposure to the released patient is not likely to exceed 5 mSv (500 mrem). The result of this dose-based release limit is that now many patients given therapeutic amounts of radioactive material no longer require hospitalization. This article presents measured dose data for 26 family members exposed to 22 patients treated for non-Hodgkin's lymphoma with 131I-anti-B1 antibody after their release according to the new NRC dose-based regulations. Methods: The patients received administered activities ranging from 0.94 to 4.77 GBq (25-129 mCi). Family members were provided with radiation monitoring devices (film badges, thermoluminescent or optically stimulated luminescent dosimeters, or electronic digital dosimeters). Radiation safety personnel instructed the family members on the proper wearing and use of the devices. Instruction was also provided on actions recommended to maintain doses to potentially exposed individuals as low as is reasonably achievable. Results: Family members wore the dosimeters for 2-17 d, with the range of measured dose values extending from 0.17 to 4.09 mSv (17-409 mrem). The average dose for infinite time based on dosimeter readings was 32% of the predicted doses projected to be received by the family members using the NRC method provided in regulatory guide 8.39. Conclusion: Therapy with 131I-anti-B1 antibody can be conducted on an outpatient basis using the established recommended protocol. The patients can be released immediately with confidence that doses to other individuals will be below the 5-mSv (500 mrem) limit.

Original languageEnglish
Pages (from-to)907-915
Number of pages9
JournalJournal of Nuclear Medicine
Volume42
Issue number6
StatePublished - 2001
Externally publishedYes

Fingerprint

Anti-Idiotypic Antibodies
Outpatients
Therapeutics
Radiation Monitoring
Film Dosimetry
Equipment and Supplies
iodine-131 anti-B1 antibody
Radiation Exposure
Non-Hodgkin's Lymphoma
Reading
Hospitalization
Radiation
Safety
Radiation Dosimeters

All Science Journal Classification (ASJC) codes

  • Radiological and Ultrasound Technology

Cite this

Rutar, F. J., Augustine, S. C., Colcher, D., Siegel, J. A., Jacobson, D. A., Tempero, M. A., ... Vose, J. M. (2001). Outpatient treatment with 131I-anti-B1 antibody: Radiation exposure to family members. Journal of Nuclear Medicine, 42(6), 907-915.

Outpatient treatment with 131I-anti-B1 antibody : Radiation exposure to family members. / Rutar, F. J.; Augustine, Samuel C.; Colcher, D.; Siegel, J. A.; Jacobson, D. A.; Tempero, M. A.; Dukat, V. J.; Hohenstein, M. A.; Gobar, L. S.; Vose, J. M.

In: Journal of Nuclear Medicine, Vol. 42, No. 6, 2001, p. 907-915.

Research output: Contribution to journalArticle

Rutar, FJ, Augustine, SC, Colcher, D, Siegel, JA, Jacobson, DA, Tempero, MA, Dukat, VJ, Hohenstein, MA, Gobar, LS & Vose, JM 2001, 'Outpatient treatment with 131I-anti-B1 antibody: Radiation exposure to family members', Journal of Nuclear Medicine, vol. 42, no. 6, pp. 907-915.
Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA et al. Outpatient treatment with 131I-anti-B1 antibody: Radiation exposure to family members. Journal of Nuclear Medicine. 2001;42(6):907-915.
Rutar, F. J. ; Augustine, Samuel C. ; Colcher, D. ; Siegel, J. A. ; Jacobson, D. A. ; Tempero, M. A. ; Dukat, V. J. ; Hohenstein, M. A. ; Gobar, L. S. ; Vose, J. M. / Outpatient treatment with 131I-anti-B1 antibody : Radiation exposure to family members. In: Journal of Nuclear Medicine. 2001 ; Vol. 42, No. 6. pp. 907-915.
@article{c9af3cbcf36349669f094bf949fd9e00,
title = "Outpatient treatment with 131I-anti-B1 antibody: Radiation exposure to family members",
abstract = "The Nuclear Regulatory Commission (NRC) regulations that govern release of patients administered radioactive material have been revised to include dose-based criteria in addition to the conventional activity-based criteria. A licensee may now release a patient if the total effective dose equivalent to another individual from exposure to the released patient is not likely to exceed 5 mSv (500 mrem). The result of this dose-based release limit is that now many patients given therapeutic amounts of radioactive material no longer require hospitalization. This article presents measured dose data for 26 family members exposed to 22 patients treated for non-Hodgkin's lymphoma with 131I-anti-B1 antibody after their release according to the new NRC dose-based regulations. Methods: The patients received administered activities ranging from 0.94 to 4.77 GBq (25-129 mCi). Family members were provided with radiation monitoring devices (film badges, thermoluminescent or optically stimulated luminescent dosimeters, or electronic digital dosimeters). Radiation safety personnel instructed the family members on the proper wearing and use of the devices. Instruction was also provided on actions recommended to maintain doses to potentially exposed individuals as low as is reasonably achievable. Results: Family members wore the dosimeters for 2-17 d, with the range of measured dose values extending from 0.17 to 4.09 mSv (17-409 mrem). The average dose for infinite time based on dosimeter readings was 32{\%} of the predicted doses projected to be received by the family members using the NRC method provided in regulatory guide 8.39. Conclusion: Therapy with 131I-anti-B1 antibody can be conducted on an outpatient basis using the established recommended protocol. The patients can be released immediately with confidence that doses to other individuals will be below the 5-mSv (500 mrem) limit.",
author = "Rutar, {F. J.} and Augustine, {Samuel C.} and D. Colcher and Siegel, {J. A.} and Jacobson, {D. A.} and Tempero, {M. A.} and Dukat, {V. J.} and Hohenstein, {M. A.} and Gobar, {L. S.} and Vose, {J. M.}",
year = "2001",
language = "English",
volume = "42",
pages = "907--915",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "6",

}

TY - JOUR

T1 - Outpatient treatment with 131I-anti-B1 antibody

T2 - Radiation exposure to family members

AU - Rutar, F. J.

AU - Augustine, Samuel C.

AU - Colcher, D.

AU - Siegel, J. A.

AU - Jacobson, D. A.

AU - Tempero, M. A.

AU - Dukat, V. J.

AU - Hohenstein, M. A.

AU - Gobar, L. S.

AU - Vose, J. M.

PY - 2001

Y1 - 2001

N2 - The Nuclear Regulatory Commission (NRC) regulations that govern release of patients administered radioactive material have been revised to include dose-based criteria in addition to the conventional activity-based criteria. A licensee may now release a patient if the total effective dose equivalent to another individual from exposure to the released patient is not likely to exceed 5 mSv (500 mrem). The result of this dose-based release limit is that now many patients given therapeutic amounts of radioactive material no longer require hospitalization. This article presents measured dose data for 26 family members exposed to 22 patients treated for non-Hodgkin's lymphoma with 131I-anti-B1 antibody after their release according to the new NRC dose-based regulations. Methods: The patients received administered activities ranging from 0.94 to 4.77 GBq (25-129 mCi). Family members were provided with radiation monitoring devices (film badges, thermoluminescent or optically stimulated luminescent dosimeters, or electronic digital dosimeters). Radiation safety personnel instructed the family members on the proper wearing and use of the devices. Instruction was also provided on actions recommended to maintain doses to potentially exposed individuals as low as is reasonably achievable. Results: Family members wore the dosimeters for 2-17 d, with the range of measured dose values extending from 0.17 to 4.09 mSv (17-409 mrem). The average dose for infinite time based on dosimeter readings was 32% of the predicted doses projected to be received by the family members using the NRC method provided in regulatory guide 8.39. Conclusion: Therapy with 131I-anti-B1 antibody can be conducted on an outpatient basis using the established recommended protocol. The patients can be released immediately with confidence that doses to other individuals will be below the 5-mSv (500 mrem) limit.

AB - The Nuclear Regulatory Commission (NRC) regulations that govern release of patients administered radioactive material have been revised to include dose-based criteria in addition to the conventional activity-based criteria. A licensee may now release a patient if the total effective dose equivalent to another individual from exposure to the released patient is not likely to exceed 5 mSv (500 mrem). The result of this dose-based release limit is that now many patients given therapeutic amounts of radioactive material no longer require hospitalization. This article presents measured dose data for 26 family members exposed to 22 patients treated for non-Hodgkin's lymphoma with 131I-anti-B1 antibody after their release according to the new NRC dose-based regulations. Methods: The patients received administered activities ranging from 0.94 to 4.77 GBq (25-129 mCi). Family members were provided with radiation monitoring devices (film badges, thermoluminescent or optically stimulated luminescent dosimeters, or electronic digital dosimeters). Radiation safety personnel instructed the family members on the proper wearing and use of the devices. Instruction was also provided on actions recommended to maintain doses to potentially exposed individuals as low as is reasonably achievable. Results: Family members wore the dosimeters for 2-17 d, with the range of measured dose values extending from 0.17 to 4.09 mSv (17-409 mrem). The average dose for infinite time based on dosimeter readings was 32% of the predicted doses projected to be received by the family members using the NRC method provided in regulatory guide 8.39. Conclusion: Therapy with 131I-anti-B1 antibody can be conducted on an outpatient basis using the established recommended protocol. The patients can be released immediately with confidence that doses to other individuals will be below the 5-mSv (500 mrem) limit.

UR - http://www.scopus.com/inward/record.url?scp=0034976931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034976931&partnerID=8YFLogxK

M3 - Article

VL - 42

SP - 907

EP - 915

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 6

ER -